The Pain Market Outlook to 2016

Aug 09, 2011, 04:30 ET from Reportlinker

NEW YORK, Aug. 9, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Pain Market Outlook to 2016

http://www.reportlinker.com/p0591017/The-Pain-Market-Outlook-to-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Introduction

The heterogeneity of pain necessitates a wide range of analgesics with different modes of action and delivery methods. As such, many different classes of drugs co-exist in the pain market. However, despite the wide range of treatment options, pain remains inadequately managed and substantial market opportunities exist for developers in chronic pain and neuropathic pain.

Features and benefits

* Assess the forecast epidemiology and development of the pain market across the 7MM.

* Analyze the dynamics of the global pain market and understand the impact of key R&D events, market trends, and issues.

* Gain up-to-date competitive intelligence and understand the major issues affecting key pharmaceutical marketers and product development.

* Forecast revenues for major currently marketed and pipeline pain products over 2010–16

* Develop strategies for success in the future global pain market.

Highlights

The global pain market recorded sales of $22.0bn in 2010, rising at a compound annual growth rate (CAGR) of 8.9% from 2005. This growth was supported by the presence of five blockbuster pain drugs - OxyContin, Lyrica, Cymbalta, Celebrex and Lidoderm. However, as patent expiries loom, the global market value is set to contract to $18.7bn by 2016.

The pain pipeline is vast, featuring over 200 drugs in clinical development. Chronic pain remains the most studied indication, although there remains strong interest in neuropathic pain and acute pain. Tapentadol ER has the greatest potential of any pipeline drug, with superior tolerability to OxyContin and potential efficacy in neuropathic pain.

Pfizer was the market-leading company in the global pain market, registering $6.4bn in sales in 2010. Collectively, the top five pain companies accounted for 76.1% of the global market. This dominance is set to wane as their pipelines will be unable to restore market share lost to generics and new product launches.

Your key questions answered

* What are the drivers and resistors of the pain market worldwide?

* What market and pipeline developments are shaping the strategies of leading pharmaceutical companies in the pain market?

* What is the commercial potential of the most promising compounds in clinical development?

* Who were the leading players in the global pain market in 2010?

Executive Summary

Overview of health technology assessment

National HTA organizations profiled

HTA in practice

Influence of HTA on pricing and reimbursement

Industry's role in HTA

Future perspectives

About the author

Disclaimer

Overview of health technology assessment

Summary

Introduction

Definition of HTA

HTA processes

Evolution of HTA

Collaborative initiatives

INAHTA

HTAi

EuroScan

EUnetHTA

Key HTA principles

Influence of HTA on pharma/medtech

National HTA organizations profiled

Summary

Introduction

Australia

PBAC

MSAC

PLAC

Canada

CADTH

Provincial HTA organizations

France

Pharmaceutical HTA

Medical device HTA

MTAs

Germany

G-BA

IQWiG

DAHTA@DIMDI

UK

NICE technology appraisals

Evaluation Pathway Program

NIHR HTA

US

CMS

AHRQ

PCORI

DERP

Private sector

HTA in practice

Summary

Introduction

Transparency

Stakeholder involvement

Patient input

Canada's new process for CDR

Calculating cost-effectiveness

NICE threshold

Theoretical thresholds

Cost minimization

Efficiency frontier

Cost-consequence analysis

Timeliness of HTA

Influence of HTA on pricing and reimbursement

Summary

Introduction

Uptake of HTA advice by payors

Australian government overrides PBAC advice

Listing of drugs assessed centrally in Canada

Dual recommendations in France

Pharmaceuticals

Medical devices

Reassessment

Germany's new early assessment procedure

HTA of older products

Implementation of advice by providers

Future role of NICE

Changing US landscape

CMS coverage of Provenge

Tackling uncertainty

US CED

Ontario's cancer drug scheme

UK patient access schemes

Managed entry in Australia

Industry's role in HTA

Summary

Introduction

European Tapestry Network

Swiss HTA consensus

Industry case study

Industry relationship with payors/policy-makers

Regulator/HTA/payor interaction

UK pilot parallel scientific advice process

Sweden's experience with parallel advice

US collaboration

Future perspectives

Summary

Introduction

Increased scope of HTA

Orphan drugs

HTA as part of product development

HTA and market access schemes

Convergence of HTA programs

EU HTA co-operation

Relative effectiveness/comparative effectiveness

Summary of conclusions

Appendix

Scope

Methodology

Secondary research

Glossary/Abbreviations

To order this report:

Drug and Medication Industry: The Pain Market Outlook to 2016

Drug and Medication Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com